Mithra Announces Belux Agreement with Ceres Pharma Worth over EUR 40 Million

  • Mithra to receive EUR 20 million upon signing, with further EUR 20 million in potential additional earn-outs
  • Agreement covers the sale of the Women’s Health branded generics business in Belgium and Luxembourg as well as License and Supply agreements for certain Mithra assets in the region
  • Divestment of BeLux portfolio in line with Mithra’s strategy to realize the value of its noncore assets and fully focus on its key value-driving pipeline
Liège, Belgium, 30 July 2018, 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has signed a comprehensive BeLux partnership with Ceres Pharma, a Belgium-based company focused on over-the-counter (OTC) and specialist healthcare.

Mithra Obtains First Marketing Authorization for Myring™ in Europe

  • Marketing authorization allows for launch of Myring™ in the United Kingdom
  • Additional marketing authorizations expected in the near future
  • Mithra to produce Myring™ at its CDMO
Liège, Belgium, 20 July 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the company obtained its first marketing authorization (MA) for Myring™  in the UK, following approval by the MHRA . Myring™ is Mithra’s contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA) and is developed to be fully bioequivalent to Merck’s Nuvaring®.  In April 2018, Nuvaring® went off patent in both the US and Europe. In the UK, which is a market worth approximately EUR 1.2 million , no generic competition exists as of yet.

Mithra and Mediner Sign LSA for Tibelia® in Hungary

  • Mithra grants exclusive license for Tibelia® to Mediner for commercialization in Hungary
  • Tibelia® is currently marketed in a 8 countries through existing license and supply agreements
  • Further Tibelia® launches anticipated in 2018

Liège, Belgium, 13 July 2018 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces an exclusive license and supply agreement (LSA) with Mediner for the commercialization of Tibelia® in Hungary.